Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp59 | Acromegaly and GH | ECE2019

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Bima Chiara , Frara Stefano , Mirra Federica , Donfrancesco Federico , Fleseriu Cara Maria , Fleseriu Maria , Giustina Andrea , Laura De Marinis , Pontecorvi Alfredo

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

ea0086pl1 | Clinical Endocrinology Trust Visiting Professor Lecture | SFEBES2022

Novel approaches for cushing’s medical management: Guidelines to clinical practice

Fleseriu Maria

A personalized patient treatment regimen for endogenous Cushing’s syndrome (CS) should be developed by a specialized multidisciplinary team, taking patient values and preferences into consideration. Comorbidities, which may compromise patient health and QoL need to be addressed, in many cases concomitant with or even before CS-specific treatments to restore eucortisolemia. Treatment of endogenous CS is initially primarily surgical and aims at complete resection of the und...

ea0073pep8.6 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Can the follow-up imaging interval for non-functioning pituitary microadenomas be extended?

Han Ashley , Varlamov Elena , Fleseriu Maria

BackgroundData on clinical characteristics and natural history of patients with non-functioning pituitary microadenomas (NFPmA) is limited to small-scale studies.MethodsA retrospective evaluation of initial clinical presentation and natural history of patients with NFPmA (conservatively managed, years; 2004–2020) was undertaken. Initial symptoms, tumor size, and pituitary function were assessed. Exclusio...

ea0073aep546 | Pituitary and Neuroendocrinology | ECE2021

A double-blind, randomized, placebo-controlled trial of SPI-62 safety and efficacy for the treatment of Cushing’s syndrome

Fleseriu Maria , Bancos Irina , Katz David

11β-hydroxysteroid dehydrogenase type 1 (HSD-1) controls the intracellular cortisol pool that has access to cytosolic glucocorticoid and mineralocorticoid receptors. HSD-1 activity is elevated in patients with Cushing’s syndrome (CS).1 Patients with CS and constitutionally low HSD-1 activity showed no hypercortisolism-related symptoms despite very high 24-hour urine free cortisol.2, 3 A recent pilot trial of a HSD-1 inhibitor in patients with classical or mild CS sho...

ea0041gp151 | Pituitary - Clinical | ECE2016

Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial

Fleseriu Maria , Melmed Shlomo , Mangal Brian , Strasburger Christian J , Biermasz Nienke R

Introduction: Although biochemical markers of acromegaly disease activity, including GH and IGF1, may fluctuate from day-to-day, biochemical treatment response in clinical trials is generally monitored using single-point analyses. Accordingly, longitudinal evaluations may assess patient status more accurately. In a phase 3 trial, oral octreotide capsules (OOC) demonstrated sustained composite endpoint GH and IGF1 response for ≤13 months in 151 patients with acromegaly pr...

ea0037gp.22.01 | Pituitary–Therapy of Cushing's disease | ECE2015

Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design

Shimatsu Akira , Sauter Nicholas , Kelly Roxzana , Unge Peter , Zhi Xin , Fleseriu Maria

Introduction: Osilodrostat is a potent, oral inhibitor of 11β-hydroxylase, the enzyme that catalyses final step of cortisol biosynthesis. In a phase II study, 15/19 patients treated with osilodrostat met the primary endpoint (normal urinary free cortisol (UFC) at 22 weeks); osilodrostat was generally well tolerated. This phase III study aims to confirm the efficacy and long-term safety of osilodrostat.Patients and methods: Adults (18–75 years) ...

ea0035p885 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Feelders Richard , Pivonello Rosario , Pedroncelli Alberto , Patino Heather , Ye Moncy , Aout Mounir , Fleseriu Maria

Background: Dopamine and somatostatin receptors on corticotroph pituitary adenomas are targets for medical treatment of Cushing’s disease (CD). Data indicate synergistic effects between pasireotide and cabergoline in improving biochemical control rates and clinical features in patients with CD.Objective: To evaluate safety and efficacy of pasireotide alone or with cabergoline in patients with CD.Methods: Patients: adults with ...

ea0070aep1074 | Hot topics (including COVID-19) | ECE2020

ACROCOVID: An international survey on care for acromegaly during the COVID-19 era

Giustina Andrea , Mario Cesana Bruno , Marks Muriël , Mortini Pietro , Khawaja Sheila , Fleseriu Maria

The COVID-19 pandemic is significantly affecting the care of chronic conditions globally. Acromegaly is a rare chronic condition with a prevalence ranging between 2.8–13.7 cases/100.000 people. Acromegaly management requires a multidisciplinary team of health care professionals (HCPs), mainly including endocrinologists, neurosurgeons, and specialized endocrine nurses. Frequent consultations, particularly during early stages of the disease, and pre/post-surgery are necess...

ea0081rc7.5 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing’s disease: findings from the phase III LINC 3 study

Pivonello Rosario , Fleseriu Maria , Akira Shimatsu , Newell-Price John , Auchus Richard , Feelders Richard , Pedroncelli Alberto , Piacentini Andrea , Biller Beverly MK

Background: Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat therapy, a potent oral 11β-hydroxylase inhibitor, rapidly normalised mean urinary free cortisol (mUFC) in most patients with CD and sustained control of mUFC over a median treatment period of 130 weeks (W). Here we describe concomitant improvements in physical manifestation...

ea0081p404 | Pituitary and Neuroendocrinology | ECE2022

Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing’s disease: Results from the Phase III, prospective LINC 3 study

Pivonello Rosario , M.K. Biller Beverly , Akira Shimatsu , Newell-Price John , Tabarin Antoine , Vila Greisa , Piacentini Andrea , Pedroncelli Alberto , Fleseriu Maria

Introduction: Osilodrostat decreases cortisol production by inhibiting 11β-hydroxylase, increasing adrenal hormones above the blockade. Here, we describe these effects of osilodrostat and associated adverse events (AEs). The efficacy and safety of osilodrostat in patients with Cushing’s disease (CD) were confirmed in the published Phase III, prospective LINC 3 study (NCT02180217).Methods: 137 patients with CD (mUFC >1.5x upper limit of norm...